Abstract
Toll-like receptors (TLRs) are evolutionary conserved transmembrane proteins that recognize a unique pattern of molecules derived from pathogens or damaged cells, triggering robust but defined innate immune responses. TLRmediated innate and/or adaptive immune responses play an important role in a variety of diseases including infectious diseases, sepsis, autoimmune diseases, allergy, and atherosclerosis. Each TLR displays a differential expression pattern, intracellular localization and signaling pathway, resulting in distinct immune responses. A variety of new TLR ligands including agonists (e.g. urinary Tamm-Horsfall glycoprotein as a TLR4 ligand, siRNA as TLR3 or 7 ligand, Plasmodium falciparum Hemozoin as a TLR9 ligand, Profilin-like protein in Toxoplasma gondii as a TLR11 ligand) and antagonists (G-rich oligodeoxynucleotides as antagonist for TLR9) have been identified, and some of other TLR ligands are already under clinical trials. The manipulation or intervention of TLR-mediated immune responses is a possible multiple ‘Toll’ gate for future developments of immunotherapies.
Keywords: Interleukin-1 receptor-associated kinase, Oligodeoxyribonucleic acids, TNF receptor-associated factor 6, immunological disorders, TLR antagonists
Current Pharmaceutical Design
Title: ‘Toll’ Gates for Future Immunotherapy
Volume: 12 Issue: 32
Author(s): Ken J. Ishii, Satoshi Uematsu and Shizuo Akira
Affiliation:
Keywords: Interleukin-1 receptor-associated kinase, Oligodeoxyribonucleic acids, TNF receptor-associated factor 6, immunological disorders, TLR antagonists
Abstract: Toll-like receptors (TLRs) are evolutionary conserved transmembrane proteins that recognize a unique pattern of molecules derived from pathogens or damaged cells, triggering robust but defined innate immune responses. TLRmediated innate and/or adaptive immune responses play an important role in a variety of diseases including infectious diseases, sepsis, autoimmune diseases, allergy, and atherosclerosis. Each TLR displays a differential expression pattern, intracellular localization and signaling pathway, resulting in distinct immune responses. A variety of new TLR ligands including agonists (e.g. urinary Tamm-Horsfall glycoprotein as a TLR4 ligand, siRNA as TLR3 or 7 ligand, Plasmodium falciparum Hemozoin as a TLR9 ligand, Profilin-like protein in Toxoplasma gondii as a TLR11 ligand) and antagonists (G-rich oligodeoxynucleotides as antagonist for TLR9) have been identified, and some of other TLR ligands are already under clinical trials. The manipulation or intervention of TLR-mediated immune responses is a possible multiple ‘Toll’ gate for future developments of immunotherapies.
Export Options
About this article
Cite this article as:
Ishii J. Ken, Uematsu Satoshi and Akira Shizuo, ‘Toll’ Gates for Future Immunotherapy, Current Pharmaceutical Design 2006; 12 (32) . https://dx.doi.org/10.2174/138161206778743484
DOI https://dx.doi.org/10.2174/138161206778743484 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Current HIV Research Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Parasites in Rheumatoid Arthritis: Imminent Threat or Protective Effect?
Current Rheumatology Reviews Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Transglutaminases as Targets for Pharmacological Inhibition
Mini-Reviews in Medicinal Chemistry B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy Transplantation of Genetically Modified Haematopoietic Stem Cells to Induce Antigen-Specific Tolerance as a Cure for Autoimmune Diseases
Current Stem Cell Research & Therapy Modulation of the Immune Response by the Cholera-like Enterotoxins
Current Topics in Medicinal Chemistry DNA Vaccines: A Mini Review
Recent Patents on DNA & Gene Sequences Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies
Current Vascular Pharmacology Editorial (Thematic Issues: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis)
Current Drug Targets An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews Regulation of the Immune Response by Natural IgM: Lessons from Warm Autoimmune Hemolytic Anemia
Current Pharmaceutical Design CD24 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: Targeting Redundancy for Immunotherapy?
Current Immunology Reviews (Discontinued)